Introduction
============

The focus of this article is the current treatment of musculoskeletal pain -- a therapeutic area that has seen many changes over the past few years. In 2002, American Pain Society guidelines for the management of osteoarthritis recommended cyclooxygenase-2 (COX-2) selective inhibitors and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) ([@b52]). However, the discovery that rofecoxib was linked to an increased incidence of myocardial infarction and stroke led to dramatic changes ([@b29]). At first it was thought that increased cardiovascular risk might be a class effect of COX-2 inhibitors, but it is now understood that the problem extends to the non-selective NSAIDs ([@b29]; [@b38]). The US Food and Drug Administration (FDA) has clearly stated that a greater risk of cardiovascular events may be a class effect for all NSAIDs ([@b25]). Although long-term clinical trials have not been conducted for most NSAIDs, the FDA concludes from the available data that their use could increase cardiovascular risk. Moreover, the gastric and renal toxicity associated with these agents is well established ([@b58]; [@b20]). This paper reviews the recent guidelines for musculoskeletal pain with an emphasis on the role of an atypical opioid, tramadol, as an option.

Current guidelines
==================

Recently, there has been a widespread re-examination of the management of musculoskeletal pain. For example, the Canadian Consensus Conference suggests that NSAIDs should be used with caution in elderly patients, who are at greatest risk of gastrointestinal, renal, and cardiovascular side effects ([@b56]). This Conference also suggests that elderly patients with osteoarthritis or rheumatoid arthritis should be treated in the context of a multi-faceted treatment plan that aims to preserve function and independence and improve quality of life. This is a good and worthwhile concept, but it is necessary to define exactly how it can be achieved.

The European League Against Rheumatism (EULAR) has just published guidelines for the management of hip osteoarthritis ([@b60]). Interestingly, these state that opioid analgesics are useful alternatives in patients in whom NSAIDs -- including COX-2 selective inhibitors -- are contra-indicated, ineffective, and/or poorly tolerated. Nearly every set of guidelines that has appeared over the past 2 or 3 years recognizes that paracetamol and opioids have a more significant role to play in the management of chronic pain.

The European Guidelines for the Management of Chronic Non-Specific Low Back Pain ([@b2]) conclude there is strong evidence that weak opioids relieve pain and disability in the short term in chronic low back pain patients. Notably, this is "level A" evidence comprising robust data. There is a clear suggestion that clinicians should decrease their use of organ-toxic NSAIDs and COX-2 inhibitors, and possibly increase the prescription of opioids.

The American Geriatrics Society Panel (AGS) on Persistent Pain in Older Persons now considers that for many older patients, chronic opioid therapy may have fewer life-threatening risks than long-term daily use of NSAIDs ([@b6]). Comparing the organ toxicity of opioids and NSAIDs, this is clearly the case.

Choice of opioid
================

Thus guidelines produced over the past 4 years have shifted their emphasis from NSAIDs and COX-2 inhibitors to opioids, which clearly makes sense in the context of musculoskeletal pain. However, strong opioids are not always required. In this setting it is interesting to consider a drug that is not a monomodal opioid -- tramadol. A better description of this agent is "a atypical centrally acting analgesic". In the central nervous system (CNS), specifically in the dorsal horn of the spinal cord, tramadol has a number of effects, as illustrated in [Figure 1](#fig1){ref-type="fig"}. Where the first order neuron transmits a pain impulse to the second order neuron, which in turn relays the information to the brain, tramadol binds to some extent to the μ-opioid receptor (its M1 metabolite does so to a greater extent) ([@b32]); this produces some of its analgesic effect and explains why, model dependent, around 40% of tramadol analgesia can be reversed by opioid antagonists ([@b43]). In addition, the descending pathways responsible for pain relief rely on monoaminergic transmission, primarily via noradrenaline and serotonin. Here, tramadol binds to the descending pathway neurons, inhibiting the re-uptake of noradrenaline and serotonin, and accounting for the remaining analgesic properties ([@b19]). Thus tramadol produces a multi-modal effect with its dual mechanism of action ([@b42]).

![Synergistic effects of tramadol at the dorsal horn ([@b16]; [@b46]).](tcrm0305-717-01){#fig1}

Traditional opioids produce analgesia but also cause constipation, respiratory depression, and sedation, as well as having a significant abuse potential ([@b57]; [@b31]; [@b8]; Cicero et al 2004). It has been clearly demonstrated that the combined opioid and monoaminergic mechanisms of tramadol can mitigate these adverse effects ([@b45]; [@b40]; [@b24]). At the same time efficacy can be increased, particularly in patients suffering from neuropathic pain, where the enhancement of monoaminergic transmission is beneficial ([@b33]; [@b53]; [@b14]). Other side effects -- dizziness, nausea, vomiting and sweating -- remain at a similar level to traditional opioids ([@b3]; [@b31]). These differences are summarized in [Table 1](#tbl1){ref-type="table"}.

###### 

Effects of traditional opioids in comparison with tramadol

                              Tramadol in comparison with typical strong opioids
  --------------------------- ----------------------------------------------------
  Analgesic efficacy          
  -- in nociceptive pain      effective
  -- in neuropathic pain      first line option
  -- in mixed pain            effective
  Abuse potential             less
  Side effects                
  -- respiratory depression   less
  -- constipation             less
  -- sedation                 less
  -- dizziness                equal
  -- nausea                   equal
  -- vomiting                 equal
  -- sweating                 equal

The efficacy and safety of tramadol in patients with musculoskeletal pain are both very well documented (see [Table 2](#tbl2){ref-type="table"}), and these have had an impact on treatment. A number of international guidelines now specifically recommend tramadol -- not just weak opioids. The American Pain Society suggests that tramadol can be used alone, or in combination with paracetamol or NSAIDs, for therapy at any stage during the treatment of a patient with osteoarthritis. The American College of Rheumatology states that the efficacy of tramadol has been found to be comparable with that of ibuprofen in patients with hip and knee osteoarthritis, and has proven useful as adjunctive therapy in patients whose symptoms are inadequately controlled by NSAIDs ([@b17]; [@b46]; [@b4]). The clear implication is that tramadol may be used instead of an NSAID, for example in patients with cardiac or renal complications ([@b58]; [@b7]). If a patient is already receiving an NSAID it can be combined with tramadol in a multi-modal analgesic approach thereby permitting dose reduction of the NSAID ([@b49]). For patients with chronic low back pain, the previously quoted European Guidelines explicitly recommend the use of "weak opioids (eg, tramadol)" in patients with non-specific chronic low back pain who do not respond to other treatment modalities (Airaksinen et al 2006).

###### 

Controlled trials of oral tramadol in patients with chronic musculoskeletal pain

  Study                      Type of pain     Study design   N     Duration   Analgesic drug                    Dosage (mg/day)     Analgesic efficacy   Adverse events
  -------------------------- ---------------- -------------- ----- ---------- --------------------------------- ------------------- -------------------- ----------------
  [@b1]                      Osteoarthritis   db             279   1 mo       SR tramadol                       150-400             SR-T = IR-T          SR-T = IR-T
                                                                              IR tramadol                       150-400                                  
  [@b11]                     Osteoarthritis   db, co         40    2 × 2 wk   IR tramadol                       200                 T \>PE               T \< PE
  [@b28]                     Chronic          db             94    1 wk       IR tramadol                       prn                 T \>TI/N             NR
                                                                              Tilidine/naloxone                 prn                                      
  Jensen and Ginsberg 1994   Osteoarthritis   db, co         264   2 wk       IR tramadol                       300                 T \>D                T \> D
  [@b39]                     Osteoarthritis   db             60    2 × 4 wk   IR tramadol                       164                 T = DI               T = DI
                                                                              Diclofenac                        97                                       
  [@b44]                     Chronic          db             990   4 wk       IR tramadol                       244                                      
                                                                              Paracetamol/codeine               1407/140            T = P/C              T = P/C
  [@b46]                     Osteoarthritis   db             63    13 d       IR tramadol + NSAID               250                 T \>PL               NR
                                                                              Placebo + NSAID                                                            
  [@b48]                     Low back         db             254   4 wk       IR tramadol                       200-400             T \>PL               T \> PL
                                                                              Placebo                                                                    
  [@b51]                     Osteoarthritis   db             308   10 d       IR tramadol/paracetamol + NSAID   150-300/1300-2600   T/P \>PL             T/P \> PL
  [@b55]                     Low back         db             205   3 wk       SR tramadol                       200                 SR-T = IR-T          SR-T = IR-T
  [@b59]                     Osteoarthritis   db             60    1 mo       SR tramadol                       200                 T \>DC               T \>DC
                                                                              IR tramadol                       200                                      
                                                                              SR dihydrocodeine                 200                                      

**Abbreviations** C, codeine; co, crossover; d, days; D, dextropropoxyphene; db, double-blind; DC, dihydrocodeine; DI, diclofenac; IR, immediate release; mo, months; N, naloxone; NR, not reported; P, paracetamol; PE, pentazocine; PL, placebo; prn, as needed; SR, sustained-release; T, tramadol; TI, tilidine; wk,weeks; \> indicates superior to; = indicates equivalent to; \< indicates inferior to.

Even in conditions where central sensitization is now thought to play an important role, there is support for the use of tramadol. For example, the Veterans Health Administration of the US Department of Defence considers tramadol to be a therapeutic intervention with some benefits for sufferers from fibromyalgia ([@b13]). In the long-term care of the elderly, the American Medical Directors Association says that tramadol is a first line pharmacological treatment for chronic pain, together with paracetamol, NSAIDs, and COX-2 inhibitors ([@b5]).

The working group on pain management
====================================

It is apparent that revised guidelines for pain management are needed, and that these will encourage greater prescription of opioids and reduced use of NSAIDs and COX-2 inhibitors, as well as specifically recommending tramadol. There is a Working Group on Pain Management which regularly publishes its findings, including guidelines ([@b47]) (on the Internet at <http://www.painworkinggroup.org>). Its recommendations today differ significantly from those issued by others before 2004.

Osteoarthritis patients without particular risk factors should receive background analgesia with up to 4 g/day of paracetamol. For a short-term flare, NSAIDs or the immediate-release paracetamol--tramadol fixed combination tablet should be administered. If this does not adequately control the pain then immediate release tramadol can be administered. An immediate-release strong opioid can be considered if the patient still experiences insufficient pain relief. For long-term pain management, NSAIDs are not recommended. The regimen is similar to that for short-term treatment but there are advantages to prescribing sustained-release tramadol formulations. These treatment regimens are summarized in [Figure 2](#fig2){ref-type="fig"}.

![Recommendations of the working group on pain management for patients with osteoarthritis.](tcrm0305-717-02){#fig2}

In elderly patients with low back pain who have no particular risk factors and require long term pain management, the working group recommends the use of a weak opioid plus paracetamol, or tramadol monotherapy (see [Figure 3](#fig3){ref-type="fig"}). NSAIDs and COX-2 inhibitors can be prescribed for young healthy adults without risk factors, but even the FDA and the European Medicines Agency ([@b23]) now state that the smallest possible dose should be used for the shortest possible time. So the paracetamol--tramadol fixed combination tablet or tramadol sustained release may be preferred. Thus the achievement of pain management goals such as improved functioning, return to work, and a better quality of life is based largely on paracetamol and tramadol.

![Recommendations of the working group on pain management for patients with low back pain.](tcrm0305-717-03){#fig3}

There is a large body of high quality evidence for using tramadol as suggested by the working group, particularly in neuropathic pain. Low back pain often has a neuropathic component, which plays a major role in the condition of patients referred to chronic pain clinics. One recent large scale study found that in an unselected cohort of chronic low back pain patients, 37% had predominantly neuropathic pain ([@b27]). This is also the pain component that is most difficult to treat in the general practice setting.

Tramadol is increasingly gaining acceptance as it is effective against both nociceptive and neuropathic pain. There have now been a considerable number of randomized, controlled trials, and a Cochrane review, that show a high efficacy of tramadol in neuropathic pain ([@b21]); the number needed to treat (NNT) compared with placebo to achieve at least 50% pain relief was 3.5 with a number needed to harm (NNH) of 7.7. Based on these favorable numbers, in the latest evidence-based algorithms for treating neuropathic pain, tramadol is very high in the sequence of drugs that should be used ([@b22]; [@b26]).

Conclusion -- the need for change
=================================

Many doctors still use NSAIDs and COX-2 inhibitors to treat musculoskeletal pain, despite the safety risks and the fact that these agents have a ceiling effect, so that continuing to increase the dose only results in a greater incidence of adverse events. Also, the inflammatory component of osteoarthritis pain is minimal ([@b10]) -- perhaps osteoarthrosis would be a more accurate term, so an anti-inflammatory drug is not needed in these patients, and NSAIDs carry the risk of organ toxicity ([@b54]; [@b37]; [@b20]; [@b36]; [@b29]). This was previously believed to be limited to the kidney and stomach but is now known to extend to the heart and cardiovascular system ([@b18]). Opioids are currently under-utilized, although they are known to be effective and have minimum organ toxicity -- possibly none in most settings -- even in long-term use ([@b12]; [@b41]). This might be of particular importance in the elderly, as they exhibit commonly already impaired or reduced organ function ([@b9]). Many guidelines have changed in the last 4 years, but have not yet been implemented in routine clinical practice.

Tramadol is now specifically recommended in musculoskeletal pain guidelines and neuropathic pain guidelines, because of its efficacy, safety, and tolerability ([@b22]; [@b21]; [@b26]). Clearly there is no major organ toxicity ([@b50]; [@b41]), and its use necessarily implies an NSAID-sparing effect ([@b49]). The improved side effect profile over traditional opioids is particularly marked in the case of constipation, which is usually the biggest problem with opioid use in the elderly. Finally, tramadol has been on the market for 30 years and clinical experience now extends to more than 5 billion patient treatment days, so the data underlying the latest guidelines are extremely robust ([@b34]).
